WINDOSR, ONTARIO, CANADA – March 17th, 2015
The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce a Company mentioned in last week’s update has surged amidst growing Investor interest.
Many factors may have been attributed to the enormous move in Propanc Health Group (OTCBB: PPCH), but traders acting early after the feature piece could have turned $9,000 into $100,000. The Company’s update in the form of a press release the next day added fuel to the fire; but many Traders are speculating that this ticker has a large short position. We feel if the chart breaks above the previous high of $0.042, after this well deserved break, the technicals (short covering, chart readers) could drive prices towards the $0.10 level. The chart looks extremely poised to jump.
Undoubtedly many eyes are on the Biotech sector and that could have been another contributing factor to the interest. And more specifically, the oncology (cancer) focused Companies have the most cheerleaders. Most Retail traders do not yet know of the awesome science milestones cancer therapies have made over the past 2 or 3 years—these new retail traders should power the sector for the foreseeable future. Futuristic treatments “ideas” that were talked about at dinner parties in the 80’s and 90’s are now a reality.
The Wealth Biotech Trader encourages all readers to watch “Killing Cancer,” a recent HBO special. Click here to watch: http://goo.gl/BMr1Ju . The Chief Investment Officer of Google Ventures, Googles Venture Capital Investment arm (a fund with a significant stake in a myriad of Biotech Companies), said it best in a recent Bloomberg article: “You can now legitimately invest in a company that can cure cancer.”
In addition to Propanc (OTCBB: PPCH), in the last release we mentioned some other notable names (Stemline Therapeutics, Inc. (NASDAQ: STML), Verastem, Inc. (NASDAQ: VSTM), CTI BioPharma Corp. (NASDAQ: CTIC). All of these companies have a novel approach to treatment of cancer which hopefully will result in the elimination of radiation therapy and chemotherapy in the not too distant future.
Propanc Health Group (OTCBB: PPCH) should be closely watched over the coming days, weeks and months to see how news from their recently announced R&D program unfolds. The Wealthy Biotech Trader will bring these updates to readers with a break-down of the technical and scientific jargon along with updates on the fundamentals of the Company.
The Wealthy Biotech Trader is researching several new trade ideas which have the makings for large market moves such as the one Propanc Health Group has undergone. Active traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through our Twitter and Facebook accounts, as well as newswire.
TO GET BREAKING NEWS FROM US:
Follow us on twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.